FDA Extends Enforcement Deadline for Drug Supply Chain Security Act (DSCSA) Requirements | by: Sumeet Singh, Founder & Chairman | Article Posted: September 6, 2023 | Introduction The U.S. Food and Drug Administration (FDA) recently announced an extension on the...
NABP Accused of Enforcing ‘Shadow Regulation’ Twice in 3 years NABP is a private organization that mostly earns revenue by offering various services...
In recent months, the reversals on policy regarding awarding extensions to the highly controversial PBM requirement has caused a lot of confusion....
DSCSA Update: Breaking Case Packs & Adoption Increases When initially signed by President Obama in 2013, industry was well aware of the sweeping...
Retail Pharmacy Headwinds: New Technology & Disruption The headwinds for retail pharmacy continue to grow as new technology and services are...
The patchwork that is state licensure is a constant challenge for all companies in the pharmaceutical supply chain – from international drug manufacturers to independent distributors. Companies not in compliance are at significant risk of being caught by state agencies and facing significant fines, having disciplinary action follow them for years, and, in one example, being forced to close their business. Most important to remember is that non-compliance typically sets off a chain reaction.
Morphine Equivalency for Suspicious Order Monitoring Background In July 2016, at the height of the opioid epidemic, the West Virginia Attorney...
